Patent: 10,213,444

Summary for Patent: 10,213,444

Title:	Composition and method for treating bipolar disorder
Abstract:	Disclosed is a composition suitable for oral administration and capable of treating individuals suffering from unipolar disorder, bipolar disorder and/or bipolar disorder with an unhealthy body weight. The composition comprises a combination therapy of minocycline and acetylsalicylic acid delivered in doses that improve metabolic function and/or exert immune-modulating and/or anti-inflammatory effects. Also disclosed is a method for treating individuals suffering from the indicated disorders.
Inventor(s):	Drevets; Wayne Curtis (Newton, PA), Yates; William Robert (Tulsa, OK), Savitz; Jonathan Bradley (Tulsa, OK), Preskorn; Sheldon H. (Wichita, KS)
Assignee:	Laureate Institute For Brain Research (Tulsa, OK)
Application Number:	15/532,851
Patent Claims:	see list of patent claims

US 10,213,444: What does the bipolar depression COX-1 + microglial cytokine delivery claim actually cover?

United States Patent 10,213,444 claims treatment of bipolar depression by delivering, as a “single drug delivery system,” two pharmacologic agents in combination: 1) a COX-1 inhibitor (explicitly capped to acetylsalicylic acid or naproxen in dependent claim sets), and
2) a cytokine-modulating agent acting via microglial cells (explicitly enumerated in dependent claims).

The independent claim language is drafted to target a specific therapeutic strategy (dual mechanism) and constrain it through:

• combination pairing (COX-1 inhibition + microglial cytokine release modulation),
• route/configuration via a “single drug delivery system,” and
• dose windows (mg/kg ranges tied to body weight) plus optional dosing frequency.

This is a narrow, composition-of-method-of-treatment claim framed around mechanism pairing and drug identity rather than around a single novel chemical entity.

---

What are the actual claim elements in US 10,213,444?

Core independent claim (Claim 1)

Claim 1 requires all of the following:

• Patient population: an individual with bipolar depression
• Method steps: delivering two compounds as one delivery system
  • Compound A: “pharmacologically effective amount” of a compound capable of inhibiting COX-1
  • Compound B: “pharmacologically effective amount” of a compound capable of modulating the release of cytokines from microglial cells in the brain
• Single drug delivery system: both active agents are delivered using a single delivery system (claim construction is critical for landscape risk allocation).

Dose and schedule sub-elements

Dependent claims add constraint layers:

• COX-1 inhibitor dose window
  • Claim 2: 0.5 to 2.0 mg/kg
  • Claim 3: 1 to 6 mg/kg
• Dosing frequency
  • Claim 4: deliver twice a day
  • Claim 5: deliver once in the morning and once in the evening
• COX-1 inhibitor identity (Claim 6)
  • acetylsalicylic acid or naproxen
• Microglial cytokine modulator identity (Claim 7)
  • minocycline
  • adalimumab
  • certolizumab pegol
  • anakinra
  • rilonacept
  • canakinumab

Body mass index (BMI) targeting (Claims 8–10)

Claim 8 limits to:

• bipolar depression patient with BMI > 25

Claim 9–10 repeat COX-1 inhibitor dose windows:

• Claim 9: 0.5 to 2.0 mg/kg
• Claim 10: 1 to 6 mg/kg

Sex stratification (Claims 11–13)

Claim 11:

• bipolar depression in a female

Claim 12:

• COX-1 inhibitor dose 0.5 to 2.0 mg/kg

Claim 13:

• cytokine modulator dose: 1 to 6 mg/kg

---

How broad is the claim coverage, practically? (Claim scope stress-test)

1) Mechanism pairing creates a “two-key” infringement requirement

To infringe, an accused method must provide:

• COX-1 inhibition and
• microglial cytokine release modulation

If a product uses a COX-2 inhibitor (or a COX-1–insufficient agent), it likely falls outside Claim 1’s core requirement. If it uses only the cytokine modulator without COX-1 inhibition, it also falls outside.

2) Dependent claims hard-code identities

The dependent claims are restrictive:

• COX-1 inhibitor is limited to acetylsalicylic acid and naproxen (Claim 6).
• Microglial cytokine modulators are limited to the enumerated list (Claim 7).

If a third-party strategy uses a different COX-1 inhibitor (e.g., another NSAID with COX-1 activity) or a cytokine modulator not in the list, the infringement posture depends on whether the alleged product maps to Claim 1 (generic COX-1 inhibitor + generic cytokine modulator) or can be avoided by moving outside the dependent enumerations while still using the same pairing.

3) “Single drug delivery system” is the largest technical landmine

Claim 1 requires both actives be delivered as one system. That phrasing can reduce infringement risk for:

• two separate formulations dosed separately (even if same day), or
• combination regimens where components are packaged independently.

However, many realities turn on claim construction:

• whether “single delivery system” includes co-formulated fixed-dose combination,
• whether it includes co-administered actives via the same device or regimen unit,
• and how “single” is interpreted when dosing is scheduled twice daily.

4) Dose windows appear to be the main quantitative fences

COX-1 inhibitor dosage ranges are explicit:

• 0.5 to 2.0 mg/kg and 1 to 6 mg/kg.

Cytokine-modulator dosage is specified only in a female/BMI-divided dependent chain (Claim 13: 1 to 6 mg/kg).

This suggests an enforcement strategy that can select targets by:

• choosing a dose outside the window to mitigate literal infringement,
• arguing non-equivalence for range overlap if challenged.

5) Patient subgrouping constrains therapeutic method coverage

Claim 8 (BMI > 25) and Claim 11 (female) narrow to subpopulations. If an accused therapy is tested or labeled for:

• men and women equally, or
• BMI-inclusive populations, enforcement may still attempt to fit into Claim 1 (less constrained than Claims 8/11) but would be easier to tailor if clinical practice targets the subgroups.

---

What claims do and do not say (gaps that matter for landscape positioning)

What the claims are not limited to

From the claim text provided, the patent is not explicitly limited to:

• a particular route (oral vs transdermal vs inhaled vs parenteral),
• a particular formulation geometry (tablet, capsule, depot, implant),
• a single specific cytokine target (the claim uses “cytokines” broadly),
• a particular microglial mechanism besides “modulating release.”

What the claims strongly imply

• The invention is anchored in a therapeutic hypothesis: COX-1 inhibition + microglial cytokine modulation helps treat bipolar depression.
• The use of monoclonal antibodies and IL-1 pathway agents in the enumerated list implies that the cytokine mechanism is mediated by neuroinflammatory signaling pathways relevant to microglial cytokine release.

---

How credible is the novelty angle versus preexisting landscapes? (Critical reading)

This claim set looks like a method-of-treatment combination that uses:

• an established NSAID class for COX inhibition (acetylsalicylic acid, naproxen), and
• immune-modulating agents known for cytokine pathway interference (e.g., anakinra, canakinumab, IL-1 related inhibitors; plus TNF inhibitors such as adalimumab/certolizumab pegol).

In the patent landscape, such structures typically face three common validity pressure points: 1) Obviousness: combining known anti-inflammatory/immune-modulating agents for neuropsychiatric inflammation theories. 2) Enablement and written description risks: broad “capable of” language versus specific functional outcomes (“modulating release of cytokines from microglial cells”) depending on how the specification supports each enumerated agent. 3) Indefiniteness risk: the phrase “single drug delivery system” can become a construction fight, and “modulating the release” can invite disputes about the required biological mechanism versus therapeutic outcome.

Still, the claim includes concrete dose windows and explicit agent lists in dependent claims, which can make a validity challenge harder if the specification teaches the combination dosing and delivery mechanics.

---

Patent landscape: where similar claim concepts cluster (what to search for)

The landscape will generally cluster around:

• neuroinflammation in bipolar depression (microglia activation, cytokine profiling, IL-1, TNF, and related pathways),
• COX inhibition in mood disorders (including NSAID adjuncts),
• combination therapies delivered as a fixed combination or via a single regimen unit.

Search map for freedom-to-operate and invalidity harvesting

Use these search anchors:

• “bipolar depression” + “microglial” + “cytokine”
• “bipolar depression” + “COX-1” or “COX-1 inhibitor”
• “single drug delivery system” + “bipolar depression” (claim language mining)
• COX-1 inhibitor identity pairs:
  • “acetylsalicylic acid” + “microglial cytokine”
  • “naproxen” + “anakinra” (and separately with the enumerated biologics)
• enumerated cytokine agents:
  • “anakinra” + “microglial”
  • “canakinumab” + “microglial”
  • “rilonacept” + “microglial”
  • “adalimumab” + “microglial”
  • “certolizumab pegol” + “microglial”
  • “minocycline” + “microglial”

Why these clusters matter for validity

A third party can attack novelty/obviousness by showing:

• each component is independently known for inflammatory/microglial modulation,
• and prior art describes co-administration or a rationale to combine.

Even without an identical bipolar depression use case, broad neuroinflammation theories can be leveraged in obviousness arguments if the patent’s claimed combination relies on general inflammatory biology rather than a bipolar-specific discovery.

---

What design-arounds most plausibly reduce infringement risk? (Claim-driven)

Given the claim structure, the highest-value design-arounds are those that break the claim’s required combinations:

1) Break “single drug delivery system”

• Use two separately administered products (separate delivery units) rather than one combined delivery system.
• Align schedules to match twice-daily timing only if that does not reinstate a “single system” characterization.

2) Break COX-1 inhibition

• Use a cytokine modulator with no COX-1 inhibitory component.
• Or use a COX inhibitor that is not a COX-1 inhibitor for infringement purposes (depending on how COX selectivity is treated in claim construction).

3) Break the enumerated drug identities in dependent claims

• If trying to avoid dependent claim coverage, use a different COX-1 inhibitor than acetylsalicylic acid/naproxen, and/or a cytokine modulator outside the enumerated list.

4) Dose-window avoidance

• If a target is a specific COX-1 inhibitor, keep dosing outside the mg/kg ranges tied to dependent claims.
• For female patients, keep cytokine-modulator dose outside 1 to 6 mg/kg.

---

Key Takeaways

• US 10,213,444 is a bipolar depression method-of-treatment patent built around a dual-mechanism pairing delivered via a “single drug delivery system”: COX-1 inhibition plus microglial cytokine release modulation.
• Coverage is narrowed by agent identity in dependent claims (acetylsalicylic acid/naproxen; and a defined list of cytokine modulating agents) and by dose windows (COX-1 inhibitor: 0.5–2 mg/kg or 1–6 mg/kg; cytokine modulator dose: 1–6 mg/kg in the female dependent chain).
• The largest practical infringement lever is the “single drug delivery system” limitation; most design-arounds will focus on disrupting that integration concept.
• Validity and landscape risk will center on whether prior art already teaches:
  • neuroinflammatory microglial cytokine modulation in bipolar depression,
  • COX inhibition as an adjunct or mechanism,
  • and any rationale or precedent for combining the two therapeutic pathways.

---

FAQs

1) Does Claim 1 require a specific cytokine target (IL-1, TNF, etc.)?

No. It requires a compound that can modulate release of cytokines from microglial cells; the claim text does not specify a single cytokine.

2) Are acetylsalicylic acid and naproxen the only COX-1 inhibitors covered?

They are explicitly listed in the dependent claim set (Claim 6). Claim 1’s COX-1 inhibitor requirement is broader, but dependent claims tie enforcement targets to those identities.

3) What is the single biggest technical ambiguity in the claims?

Whether the accused regimen qualifies as a “single drug delivery system” when components are formulated and administered in practical clinical ways.

4) Do the claims require twice-daily dosing?

Twice-daily appears in dependent claim language (Claim 4) with a morning/evening variant (Claim 5). Claim 1 itself does not mandate frequency.

5) How do BMI and female-specific claims affect enforcement?

They narrow certain dependent claim coverage to BMI > 25 (Claims 8–10) and to female patients (Claims 11–13), while leaving broader coverage potential in Claim 1.

---

References (APA)

[1] United States Patent 10,213,444. (n.d.). Patent claims excerpt provided by user.

Details for Patent 10,213,444

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	November 14, 2001		2035-12-04
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002		2035-12-04
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008		2035-12-04